Clinical Trials & Pipeline
Mirna is a clinical-stage biopharmaceutical company developing a broad pipeline of leading microRNA-based oncology therapeutics, the first to demonstrate clinical proof of concept for microRNA replacement therapy.
LEARN MORE ABOUT US
MRX34, Mirna’s lead product candidate, is the first microRNA mimic to enter clinical testing.
LEARN MORE ABOUT OUR CLINICAL TRIALS AND PIPELINE
July 5, 2016
Mirna Therapeutics to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
June 30, 2016
Mirna Therapeutics Appoints Perry Nisen, M.D., Ph.D., to Its Board of Directors
VIEW ALL NEWS
© 2015 Mirna Therapeutics, Inc. All Rights Reserved.